NCT07935564
A Study to Assess the Adverse Events and How Oral ABBV-1606 Moves Through the Body of Healthy Adult Participants.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Number of Participants Experiencing Adverse Events
Timeframe: Up to approximately 35 days
Maximum observed plasma concentration (Cmax) of ABBV-1606
Timeframe: Up to approximately 5 days
Time to maximum observed plasma concentration (Cmax) (Tmax) of ABBV-1606
Timeframe: Up to approximately 5 days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of ABBV-1606
Timeframe: Up to approximately 5 days
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of ABBV-1606
Timeframe: Up to approximately 5 days
Apparent terminal phase elimination constant (β) of ABBV-1606
Timeframe: Up to approximately 5 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1606
Timeframe: Up to approximately 5 days
Apparent clearance (CL/F) of ABBV-1606
Timeframe: Up to approximately 5 days
Apparent volume of distribution (Vz/F) of ABBV-1606
Timeframe: Up to approximately 5 days
Dose Normalized Cmax of ABBV-1606
Timeframe: Up to approximately 5 days
Dose Normalized AUC of ABBV-1606
Timeframe: Up to approximately 5 days
Arms and interventions
ABBV-1606 or Placebo Group 1Experimental
Participants will receive a single oral dose of ABBV-1606 or placebo group 1 on day 1.
ABBV-1606 or Placebo Group 2Experimental
Participants will receive a single oral dose of ABBV-1606 or placebo group 2 on day 1.
ABBV-1606 or Placebo Group 3Experimental
Participants will receive a single oral dose of ABBV-1606 or placebo group 3 on day 1.
ABBV-1606 or Placebo Group 4Experimental
Participants will receive a single oral dose of ABBV-1606 or placebo group 4 on day 1.
ABBV-1606 or Placebo Group 5Experimental
Participants will receive a single oral dose of ABBV-1606 or placebo group 5 on day 1.
Drugs: ABBV-1606, Placebo
Sites
1 site in 1 country
- Acpru /Id# 277795Grayslake, Illinois, United States